SCHEMBL25656204

SCHEMBL25656204

Cc1cc2ncnc(-c3ccc(C#N)nc3)c2cc1C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNF P01375 2/20 0.41
PIK3CD O00329 2/20 0.41
PIK3CA P42336 2/20 0.41
PIK3CB P42338 2/20 0.41
MTOR P42345 2/20 0.41
EGFR P00533 2/20 0.41
ABL1 P00519 1/20 0.41
HCK P08631 1/20 0.41
SRC P12931 1/20 0.41
KDR P35968 1/20 0.41
EPHB4 P54760 1/20 0.41
PRKDC P78527 1/20 0.41
PI4KB Q9UBF8 1/20 0.41
IRAK4 Q9NWZ3 1/20 0.41
PDE10A Q9Y233 1/20 0.41
TRPA1 O75762 1/20 0.39
EGLN2 Q96KS0 1/20 0.36
ENPP1 P22413 2/20 0.36
CHEK1 O14757 1/20 0.36
PIK3CG P48736 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23762363 0.83 PDE10A (0.61) PIK3CDPIK3CAPIK3CBMTOREGFR
SCHEMBL30080003 0.83 PDE10A (0.61) PIK3CDPIK3CAPIK3CBMTOREGFR
SCHEMBL25656213 0.78 PIK3CD (0.38) PIK3CDPIK3CAPIK3CBMTOREGFR
SCHEMBL25656212 0.78 PIK3CD (0.38) PIK3CDPIK3CAPIK3CBMTOREGFR
SCHEMBL25656203 0.75 ENPP1 (0.48) PIK3CDPIK3CAPIK3CBMTOREGFR
SCHEMBL182530 0.73 PIK3CA (0.63) TNFPIK3CDPIK3CAPIK3CBMTOR
SCHEMBL25656211 0.70 ENPP1 (0.54) PIK3CDPIK3CAPIK3CBEGFRKDR
SCHEMBL25655992 0.70 ENPP1 (0.51) PIK3CDPIK3CAPIK3CBMTORENPP1
SCHEMBL25656205 0.68 ENPP1 (0.75) ENPP1KIT
SCHEMBL19398273 0.68 MAP4K4 (0.68) IRAK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230183212-A1 INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) AND METHODS OF USE THEREOF STINGRAY THERAPEUTICS INC (US) 2023-06-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230183212-A1 INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) AND METHODS OF USE THEREOF ENPP1, ENPP3, PPA1 TNF 2074/4885PIK3CD 815/4885PIK3CA 503/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.